Details

As the number of actionable, prognostic and therapeutic biomarkers increases, it’s critical to find ways to maximize the ability to match patients with appropriate molecular treatment regimens. Find out more about how Comprehensive Genomic Profiling (CGP) is being applied to deal with the complexity of Non-Small Cell Lung Cancer (NSCLC) and hear from two industry leading experts on how they incorporate CGP into their labs, and their practices.

Watch now and learn more: 

  • Gain insights into real world applications of CGP to profile NSCLC
  • An introduction to how NSCLC is diagnosed in the Netherlands
  • How CGP can be used in first-line diagnostics

Illumina update on their IVD road map
Dr. Phil Febbo, Chief Medical Officer, Illumina

The impact of Comprehensive Genomic Profiling
Dr. Anke Homann, Associate Director of Medical Affairs, Illumina

A day in the life of a pathologist using Comprehensive Genomic Profiling
Dr. Henrik Hager, Consultant Pathology, Vejle Hospital

Dealing with complexity through Comprehensive Genomic Profiling
Prof. Ed Schuuring, Professor of Molecular Oncological Pathology, University Medical CenterGroningen

Fill Out Form to Access Webinar

Your email address is never shared with third parties.

Date & Time
17 Sep 2021
8:30 AM
Location
Europe
Topic
Oncology
Watch Now